Jivolar

Metformin Hydrochloride and Sitagliptin, the active ingredients in Jivolar, are a Biguanide and a DPP‑4 inhibitor presented as a fixed‑dose combination tablet for oral use. The medication is indicated for the management of type 2 diabetes mellitus in adult patients, particularly when glycaemic control is insufficient with metformin alone or when an additional glucose‑dependent insulin secretagogue is required.

GNH USA supplies Jivolar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets.

Jivolar combines metformin and sitagliptin to target hyperglycaemia in type 2 diabetes mellitus. - Type 2 diabetes mellitus (monotherapy): achieves improved fasting and post‑prandial glucose levels. - Type 2 diabetes mellitus (add‑on to metformin): provides additional HbA1c reduction when metformin alone is insufficient. - Type 2 diabetes mellitus (with diet and exercise): supports overall glycaemic control as part of comprehensive management.

Jivolar may be associated with a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal discomfort. - Diarrhoea: loose stools, often transient. - Headache: transient cranial pain.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute pancreatic inflammation with abdominal pain.

When prescribing Jivolar, several safety considerations should be observed. - Renal function assessment: evaluate creatinine clearance before initiating and periodically during therapy. - Hepatic impairment monitoring: use with caution in patients with liver disease due to lactic acidosis risk. - Risk of lactic acidosis: avoid in patients with conditions predisposing to hypoxia or severe infection. - Cardiovascular disease: monitor closely in patients with heart failure. - Elderly patients: start at lower dose and titrate cautiously. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Jivolar can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate renal dysfunction and increase metformin accumulation. - Cimetidine: can raise metformin plasma concentrations. - Insulin or sulfonylureas: combined use heightens risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycaemia. - Diuretics: affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and electrolytes. - Strong CYP3A4 inhibitors: may increase sitagliptin levels.